Niagen Bioscience
NAGE
46 hedge funds and large institutions have $14.7M invested in Niagen Bioscience in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 16 closing their positions.
9% more capital invested
Capital invested by funds: $13.6M → $14.7M (+$1.16M)
0% more funds holding
Funds holding: 46 → 46 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
4.95% less ownership
Funds ownership: 13.31% → 8.36% (-4.9%)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $47K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$646K |
| 2 |
Goldman Sachs
New York
|
+$519K |
| 3 |
ECM
Element Capital Management
New York
|
+$432K |
| 4 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
+$371K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.55M |
| 2 |
State Street
Boston,
Massachusetts
|
-$891K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$787K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$289K |
| 5 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$228K |
NAGE Hedge Fund Activity: Q2 2017 in Review
46 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2017, worth a combined $14.7M — up 8.6% from $13.6M a quarter earlier.
Fund positioning in NAGE was balanced in Q2 2017: 16 funds opened new positions, 16 closed out, 7 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, adding an estimated $646K. The largest seller was BlackRock, cutting an estimated $3.55M.
- 46 institutional investors held Niagen Bioscience (NAGE) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $14.7M of Niagen Bioscience stock for Q2 2017, up 8.6% quarter-over-quarter.
- 16 funds opened new Niagen Bioscience positions in Q2 2017 and 16 closed out, a net change of 0 holders.
- The largest Niagen Bioscience buyer in Q2 2017 was Millennium Management, an estimated $646K added.
- The largest Niagen Bioscience seller in Q2 2017 was BlackRock, an estimated $3.55M sold.
Based on aggregated 13F filings for Q2 2017.